📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Inhibitex

1.1 - Company Overview

Inhibitex Logo

Inhibitex

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of antibody-based products to prevent and treat bacterial and fungal infections, and small-molecule antiviral therapies targeting shingles and chronic hepatitis C; a clinical-stage biopharmaceutical company developing treatments for bacterial and viral infections.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Inhibitex

Micropharma Logo

Micropharma

HQ: Canada Website
  • Description: Provider of biotherapeutics, diagnostics, and devices for metabolic diseases, discovering and developing bacteria-based biotherapeutics and novel probiotic and enzymatic solutions through a unique approach from basic research to product development.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Micropharma company profile →
UNION Therapeutics Logo

UNION Therapeutics

HQ: Denmark Website
  • Description: Provider of clinical-stage pharmaceutical development of molecules with immunomodulatory and microbiological effects, focused on inflammatory skin disease and COVID-19. Developing Orismilast, a high-potency PDE4B/D inhibitor as an oral treatment for atopic dermatitis, hidradenitis suppurativa, psoriasis and ulcerative colitis, with Phase 2 studies (UCORIS in ulcerative colitis; IASOS in plaque psoriasis).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full UNION Therapeutics company profile →
NanoView Biosciences Logo

NanoView Biosciences

HQ: United States Website
  • Description: Provider of proprietary products supporting research, translation and delivery of precision medicine, built on a novel platform that uniquely identifies and characterizes exosomes. Offers high-throughput, cost-effective analysis, including Leprechaun for lentivirus and exosome biophysical characterization, contaminant detection, and concentration measurement using fluorescence and antibody-based methods.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NanoView Biosciences company profile →
Destiny Pharma Logo

Destiny Pharma

HQ: United Kingdom Website
  • Description: Provider of novel antimicrobial products in clinical development, including XF-73 Nasal for prevention of post-surgical Staphylococcal infections (preparing for Phase 3), NTCD-M3 to prevent recurring C. difficile gut infections (preparing for Phase 3), XF-73 Dermal for skin infections, an XF platform with a rapid mechanism that reduces resistance, and biotherapeutic programs for infection prevention.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Destiny Pharma company profile →
LigoCyte Pharmaceuticals Logo

LigoCyte Pharmaceuticals

HQ: United States Website
  • Description: Provider of vaccines and monoclonal antibodies for gastrointestinal and respiratory indications, developing novel immunomodulatory drug compounds that modify immune responses by targeting cell binding interactions for the treatment of inflammatory and infectious diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full LigoCyte Pharmaceuticals company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Inhibitex

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Inhibitex

2.2 - Growth funds investing in similar companies to Inhibitex

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Inhibitex

4.2 - Public trading comparable groups for Inhibitex

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Inhibitex

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Inhibitex

What does Inhibitex do?

Inhibitex is a provider of antibody-based products to prevent and treat bacterial and fungal infections, and small-molecule antiviral therapies targeting shingles and chronic hepatitis C; a clinical-stage biopharmaceutical company developing treatments for bacterial and viral infections.

Who are Inhibitex's competitors?

Inhibitex's competitors and similar companies include Micropharma, UNION Therapeutics, NanoView Biosciences, Destiny Pharma, and LigoCyte Pharmaceuticals.

Where is Inhibitex headquartered?

Inhibitex is headquartered in United States.

How many employees does Inhibitex have?

Inhibitex has 1,000 employees 🔒.

When was Inhibitex founded?

Inhibitex was founded in 2010 🔒.

What sector and industry vertical is Inhibitex in?

Inhibitex is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Inhibitex

Who are the top strategic acquirers in Inhibitex's sector and industry

Top strategic M&A buyers and acquirers in Inhibitex's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Inhibitex?

Top strategic M&A buyers groups and sectors for Inhibitex include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Inhibitex's sector and industry vertical

Which are the top PE firms investing in Inhibitex's sector and industry vertical?

Top PE firms investing in Inhibitex's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Inhibitex's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Inhibitex's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Inhibitex's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Inhibitex include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Inhibitex's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Inhibitex?

The key public trading comparables and valuation benchmarks for Inhibitex include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Inhibitex for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Inhibitex with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Inhibitex's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Inhibitex with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Inhibitex's' sector and industry vertical?

Access recent funding rounds and capital raises in Inhibitex's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Inhibitex